Abstract
Currently HER-2/neu status in breast cancer is categorized by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) in clinical practice. The amplification of the HER-2/neu gene has a prognostic significance. Quantitative determination of HER-2/neu gene amplification by qPCR or over-expression by qRT-PCR is not routinely used, whereas qPCR based assays can be an alternative method to evaluate HER-2/neu status. We searched literature and databases including the National Institutes of Health’s (NIH), National Library of Medicine (NLM), The National Center for Biotechnology Information (NCBI), PubMed, and Google Scholar. The current study aimed to identify the correlation between FISH, IHC, and real-time-PCR reaction in measuring HER-2/neu expression in breast cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
